Evidence map›Paper›PMID 38282096›Full record

ArticleCell death discovery2024

ARK5 enhances cell survival associated with mitochondrial morphological dynamics from fusion to fission in human multiple myeloma cells.

Sivasundaram Karnan, Ichiro Hanamura, Akinobu Ota, Lam Quang Vu, Kaori Uchino, Tomohiro Horio, Satsuki Murakami, Shohei Mizuno, Md Lutfur Rahman, Md Wahiduzzaman and 9 more

Open access · goldAbstract read
In one paragraph

Article in Cell death discovery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. NUAK: never underestimate a kinase.Essays in biochemistry · 2024
    Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 3 countries.

Sivasundaram Karnan *Department of Biochemistry, Aichi Medical University, Nagakute, Aichi, Japan.ORCID http://orcid.org/0000-0003-2165-7565
Ichiro Hanamura *Division of Hematology, Department of Internal Medicine, Aichi Medical University, Nagakute, Aichi, Japan. hanamura@aichi-med-u.ac.jp.ORCID http://orcid.org/0000-0002-6681-8927
Akinobu Ota *Department of Biochemistry, Aichi Medical University, Nagakute, Aichi, Japan.ORCID http://orcid.org/0000-0002-6296-2921
Lam Quang VuDivision of Hematology, Department of Internal Medicine, Aichi Medical University, Nagakute, Aichi, Japan.
Kaori UchinoDivision of Hematology, Department of Internal Medicine, Aichi Medical University, Nagakute, Aichi, Japan.ORCID http://orcid.org/0000-0003-2983-2129
Tomohiro HorioDivision of Hematology, Department of Internal Medicine, Aichi Medical University, Nagakute, Aichi, Japan.
Satsuki MurakamiDivision of Hematology, Department of Internal Medicine, Aichi Medical University, Nagakute, Aichi, Japan.
Shohei MizunoDivision of Hematology, Department of Internal Medicine, Aichi Medical University, Nagakute, Aichi, Japan.
Md Lutfur RahmanEuGEF Research Foundation, Chattogram, Bangladesh.
Md WahiduzzamanEuGEF Research Foundation, Chattogram, Bangladesh.ORCID http://orcid.org/0000-0001-5915-8935
Muhammad Nazmul HasanDepartment of Biochemistry, Aichi Medical University, Nagakute, Aichi, Japan.ORCID http://orcid.org/0000-0003-2536-7557
Mrityunjoy BiswasDepartment of Biochemistry, Aichi Medical University, Nagakute, Aichi, Japan.
Toshinori HyodoDepartment of Biochemistry, Aichi Medical University, Nagakute, Aichi, Japan.
Hideaki ItoDepartment of Pathology, Aichi Medical University, Nagakute, Aichi, Japan.
Atsushi SuzukiHematology Medical Franchise, Department of Medical Affairs, Novartis Japan, Tokyo, Japan.
Hiroyuki KonishiDepartment of Biochemistry, Aichi Medical University, Nagakute, Aichi, Japan.ORCID http://orcid.org/0000-0003-1131-4905
Shinobu TsuzukiDepartment of Biochemistry, Aichi Medical University, Nagakute, Aichi, Japan.
Yoshitaka HosokawaDepartment of Biochemistry, Aichi Medical University, Nagakute, Aichi, Japan.
Akiyoshi TakamiDivision of Hematology, Department of Internal Medicine, Aichi Medical University, Nagakute, Aichi, Japan.ORCID http://orcid.org/0000-0002-1822-9976
Aichi Medical University · JPEmory University · USKinjo Gakuin University · JPNovartis (Japan) · JPWinthrop-University Hospital · US

Funding

Ministry of Education, Culture, Sports, Science and Technology (MEXT) 19K08825, 22K08516[Hanamura]Ministry of Education, Culture, Sports, Science and Technology (MEXT) 19K09292, 22K08985 [Karnan]Ministry of Education, Culture, Sports, Science and Technology (MEXT) 21K08426 [Ota]
6 · The paper itself

Abstract

5' adenosine monophosphate-activated protein kinase-related kinase 5 (ARK5) is involved in mitochondrial ATP production and associated with poor prognosis of multiple myeloma (MM). However, the molecular mechanisms of ARK5 in MM remain largely unknown. This study examined the pathogenic role of ARK5 in mitochondria by using genetically modified isogenic cell clones with or without ARK5 in human myeloma cell lines, KMS-11 and Sachi, which overexpress ARK5. The biallelic knockout of ARK5 (ARK5-KO) inhibited cell proliferation, colony formation, and migration with increased apoptosis. Mitochondrial fusion was enhanced in ARK5-KO cells, unlike in ARK5 wild-type (ARK5-WT) cells, which exhibited increased mitochondrial fission. Furthermore, ARK5-KO cells demonstrated a lower phosphorylated dynamin-related protein 1 at serine 616, higher protein expression of mitofusin-1 (MFN1) and MFN2, optic atrophy 1 with a lower level of ATP, and higher levels of lactate and reactive oxygen species than ARK5-WT cells. Our findings suggest that ARK5-enhanced myeloma cells can survive associated mitochondrial fission and activity. This study first revealed the relationship between ARK5 and mitochondrial morphological dynamics. Thus, our outcomes show novel aspects of mitochondrial biology of ARK5, which can afford a more advanced treatment approach for unfavorable MM expressing ARK5.

Identifiers

PMID38282096
PMCPMC10822851
OpenAlexW4391311598

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.